246 related articles for article (PubMed ID: 30520145)
21. Treatment outcome of oral tofacitinib and ruxolitinib in patients with alopecia areata: A systematic review and meta-analysis.
Yu DA; Kim YE; Kwon O; Park H
Indian J Dermatol Venereol Leprol; 2021; 87(5):621-627. PubMed ID: 34379968
[TBL] [Abstract][Full Text] [Related]
22. Tofacitinib for the treatment of alopecia areata and variants in adolescents.
Craiglow BG; Liu LY; King BA
J Am Acad Dermatol; 2017 Jan; 76(1):29-32. PubMed ID: 27816292
[TBL] [Abstract][Full Text] [Related]
23. A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results.
King B; Guttman-Yassky E; Peeva E; Banerjee A; Sinclair R; Pavel AB; Zhu L; Cox LA; Craiglow B; Chen L; Banfield C; Page K; Zhang W; Vincent MS
J Am Acad Dermatol; 2021 Aug; 85(2):379-387. PubMed ID: 33757798
[TBL] [Abstract][Full Text] [Related]
24. Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients.
Liu LY; Craiglow BG; Dai F; King BA
J Am Acad Dermatol; 2017 Jan; 76(1):22-28. PubMed ID: 27816293
[TBL] [Abstract][Full Text] [Related]
25. Tofacitinib Citrate for the Treatment of Nail Dystrophy Associated With Alopecia Universalis.
Dhayalan A; King BA
JAMA Dermatol; 2016 Apr; 152(4):492-3. PubMed ID: 26630079
[No Abstract] [Full Text] [Related]
26. Successful treatment of moderate-to-severe alopecia areata improves health-related quality of life.
Liu LY; Craiglow BG; King BA
J Am Acad Dermatol; 2018 Mar; 78(3):597-599.e2. PubMed ID: 29128459
[No Abstract] [Full Text] [Related]
27. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata.
Kennedy Crispin M; Ko JM; Craiglow BG; Li S; Shankar G; Urban JR; Chen JC; Cerise JE; Jabbari A; Winge MC; Marinkovich MP; Christiano AM; Oro AE; King BA
JCI Insight; 2016 Sep; 1(15):e89776. PubMed ID: 27699252
[TBL] [Abstract][Full Text] [Related]
28. Oral tofacitinib: a promising treatment in atopic dermatitis, alopecia areata and vitiligo.
Vu M; Heyes C; Robertson SJ; Varigos GA; Ross G
Clin Exp Dermatol; 2017 Dec; 42(8):942-944. PubMed ID: 29034491
[No Abstract] [Full Text] [Related]
29. Response of alopecia areata of the beard to oral tofacitinib.
Kerkemeyer KLS; John JM; Sinclair R; Bhoyrul B
J Am Acad Dermatol; 2020 May; 82(5):1228-1230. PubMed ID: 31678329
[No Abstract] [Full Text] [Related]
30. Effectiveness and safety of generic tofacitinib in alopecia areata: is the generic a cost-effective option? A retrospective study.
Jian J; Li M; Qian P; Li J; Tang Y; Liu F; Zhao Z; Huang J; Shi W
Arch Dermatol Res; 2024 May; 316(5):154. PubMed ID: 38734794
[No Abstract] [Full Text] [Related]
31. Alopecia universalis unresponsive to treatment with tofacinitib: report of a case with a brief review of the literature.
Salman A; Sarac G; Ergun T
Dermatol Online J; 2017 Jul; 23(7):. PubMed ID: 29469706
[TBL] [Abstract][Full Text] [Related]
32. Tofacitinib for the treatment of alopecia areata in preadolescent children.
Craiglow BG; King BA
J Am Acad Dermatol; 2019 Feb; 80(2):568-570. PubMed ID: 30195571
[No Abstract] [Full Text] [Related]
33. Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents.
Liu LY; King BA
J Investig Dermatol Symp Proc; 2018 Jan; 19(1):S18-S20. PubMed ID: 29273099
[TBL] [Abstract][Full Text] [Related]
34. Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation.
Gomez-Arteaga A; Margolskee E; Wei MT; van Besien K; Inghirami G; Horwitz S
Leuk Lymphoma; 2019 Jul; 60(7):1626-1631. PubMed ID: 30997845
[No Abstract] [Full Text] [Related]
35. [JAK inhibitor].
Yamaoka K; Tanaka Y
Nihon Rinsho; 2013 Jul; 71(7):1243-7. PubMed ID: 23961674
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic synergy between contact dermatitis from a wig-fixing device and tofacitinib on alopecia areata.
Lee JS; Yoon HS; Cho S; Park HS
J Dermatol; 2019 Apr; 46(4):e139-e140. PubMed ID: 30204259
[No Abstract] [Full Text] [Related]
37. Janus kinase inhibition as a potential strategy for the treatment of psoriasis: state of the art and future perspectives.
Cassano N; Vena GA
J Biol Regul Homeost Agents; 2012; 26(4):587-96. PubMed ID: 23241109
[TBL] [Abstract][Full Text] [Related]
38. Nail involvement in patients with moderate-to-severe alopecia areata treated with oral tofacitinib.
Lee JS; Huh CH; Kwon O; Yoon HS; Cho S; Park HS
J Dermatolog Treat; 2018 Dec; 29(8):819-822. PubMed ID: 29658800
[TBL] [Abstract][Full Text] [Related]
39. Translational Positioning of Janus Kinase (JAK) Inhibitors in Alopecia Areata.
Blume-Peytavi U; Vogt A
EBioMedicine; 2015 Apr; 2(4):282-3. PubMed ID: 26137570
[No Abstract] [Full Text] [Related]
40. Pfizer's first-in-class JAK inhibitor pricey for rheumatoid arthritis market.
Garber K
Nat Biotechnol; 2013 Jan; 31(1):3-4. PubMed ID: 23302910
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
